Paratek Pharmaceuticals - PRTK Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.58
  • Forecasted Upside: 60.31%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.23
▲ +0.04 (1.83%)
Get New Paratek Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRTK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRTK

Analyst Price Target is $3.58
▲ +60.31% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Paratek Pharmaceuticals in the last 3 months. The average price target is $3.58, with a high forecast of $5.00 and a low forecast of $2.15. The average price target represents a 60.31% upside from the last price of $2.23.

This chart shows the closing price for PRTK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 polled investment analysts is to hold stock in Paratek Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/28/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/7/2023HC WainwrightReiterated RatingNeutral ➝ Neutral$2.15Low
6/7/2023HC WainwrightDowngradeBuy ➝ NeutralLow
6/7/2023Jefferies Financial GroupDowngradeBuy ➝ HoldLow
5/10/2023HC WainwrightLower Target$10.00 ➝ $6.00N/A
5/9/2023BTIG ResearchLower Target$24.00 ➝ $5.00Low
3/20/2023HC WainwrightLower Target$20.00 ➝ $10.00Low
5/6/2022HC WainwrightLower Target$22.00 ➝ $20.00Low
4/11/2022BTIG ResearchLower Target$34.00 ➝ $30.00High
3/17/2022HC WainwrightLower TargetBuy$27.00 ➝ $22.00High
2/10/2022WBB SecuritiesUpgradeBuy ➝ Strong-Buy$11.00High
11/9/2021HC WainwrightLower TargetBuy$28.00 ➝ $27.00High
6/21/2021HC WainwrightBoost TargetBuy$22.00 ➝ $28.00High
4/29/2021WBB SecuritiesUpgradeSpeculative Buy ➝ Buy$10.00Low
4/23/2021WBB SecuritiesUpgradeSpeculative Buy ➝ Buy$6.00 ➝ $10.00Medium
3/4/2021SVB LeerinkReiterated RatingBuy$14.00High
3/2/2021Jefferies Financial GroupInitiated CoverageBuy$15.00Medium
2/8/2021HC WainwrightReiterated RatingBuyMedium
11/9/2020HC WainwrightBoost TargetBuy$19.00 ➝ $22.00High
8/11/2020HC WainwrightBoost TargetBuy$18.00 ➝ $19.00High
8/11/2020SVB LeerinkLower TargetOutperform$15.00 ➝ $14.00High
3/9/2020WedbushReiterated RatingOutperformHigh
2/26/2020HC WainwrightReiterated RatingBuyLow
1/27/2020SVB LeerinkReiterated RatingOutperformLow
1/8/2020WBB SecuritiesInitiated CoverageBuy$6.00Medium
12/18/2019BTIG ResearchSet TargetBuy$36.00N/A
11/14/2019HC WainwrightLower TargetBuy$27.00 ➝ $18.00Low
11/4/2019HC WainwrightSet TargetBuy$27.00Medium
10/20/2019HC WainwrightReiterated RatingBuy$27.00Low
9/9/2019HC WainwrightSet TargetBuy$27.00High
6/26/2019HC WainwrightReiterated RatingBuyLow
5/9/2019WedbushReiterated RatingOutperform$17.00 ➝ $12.00High
5/9/2019LADENBURG THALM/SH SHReiterated RatingBuyHigh
(Data available from 4/20/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/23/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/20/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Paratek Pharmaceuticals logo
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $2.23
Low: $2.19
High: $2.24

50 Day Range

MA: $2.22
Low: $2.17
High: $2.23

52 Week Range

Now: $2.23
Low: $1.29
High: $3.65

Volume

4,764,400 shs

Average Volume

724,253 shs

Market Capitalization

$127.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Paratek Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Paratek Pharmaceuticals in the last twelve months: BTIG Research, HC Wainwright, Jefferies Financial Group Inc., and StockNews.com.
View the latest analyst ratings for PRTK.

What is the current price target for Paratek Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Paratek Pharmaceuticals in the last year. Their average twelve-month price target is $3.58, suggesting a possible upside of 60.3%. BTIG Research has the highest price target set, predicting PRTK will reach $5.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $2.15 for Paratek Pharmaceuticals in the next year.
View the latest price targets for PRTK.

What is the current consensus analyst rating for Paratek Pharmaceuticals?

Paratek Pharmaceuticals currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PRTK, but not buy more shares or sell existing shares.
View the latest ratings for PRTK.

What other companies compete with Paratek Pharmaceuticals?

How do I contact Paratek Pharmaceuticals' investor relations team?

Paratek Pharmaceuticals' physical mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company's listed phone number is (617) 807-6600 and its investor relations email address is [email protected]. The official website for Paratek Pharmaceuticals is www.paratekpharma.com. Learn More about contacing Paratek Pharmaceuticals investor relations.